



PHYLOGICA

BEYOND ANTIBODIES



AGM
November, 2005

Aki von Roy Chairman
Stewart Washer CEO

Chairman's Address

- Phylogica has made good progress in a number of key areas since listing in March this year.
- We now have US, EU and AU patent protection over our drug discovery technology that has already yielded drug candidates in stroke, asthma and diabetes.
- Our stroke drug candidates have been proven in tests. Stroke is a disease with no current cure.
- The Federal Government has backed our technology and granted \$2.3m towards our drug development programs.
- We look forward to the successes of this next year and thank you for your continued support.



Overview


- Biopharmaceutical company - therapeutic peptides
- Spin-off from Telethon Institute for Child Health Research (AUS) and Fox Chase Cancer Center (USA)
- Experienced and proven board and management team with international reach
- Dominant international patent portfolio protecting drug discovery platform
- Stroke drug lead and drug candidate portfolio
- Simple business model with early revenue
- Supported by expert biotech analysts

Phylogica Limited

leaders in peptide drug discovery

- **Mission**

Phylogica is developing new therapies for inflammatory diseases using a proprietary drug discovery technology



PHYLOGICA
BEYOND ANTIBODIES

Company History

strong strategic partnerships

Fox Chase Cancer
Center (USA)

Board &
Management

Telethon Institute for
Child Health Research
(Australia)

Phylogica Ltd

All Intellectual Property is wholly owned by Phylogica
6 years in development



PHYLOGICA
BEYOND ANTIBODIES

Board and Management

a blend of experience and expertise



Mr Joachim (Aki) von Roy – Chairman

- Former President of Bristol-Myers Squibb, Europe
- Over 30 years international experience in pharmaceutical companies, including Schering AG and Bristol-Myers Squibb



Dr Stewart Washer – Chief Executive Officer

- Over 12 years of CEO and Board experience in commercial biotechnology companies
- Member of the Australian Federal Government Advisory Council on Intellectual Property
- Proven track record in building profitable biotech companies



Dr Paul Watt – Executive Director and Chief Scientific Officer

- Over 5 years commercial biotechnology experience
- Commonwealth Overseas Scholarship recipient, completed his doctorate at the University of Oxford
- Post Doctoral appointments at Oxford and Harvard Universities

PHYLOGICA

BEYOND ANTIBODIES

Board and Management

a blend of experience and expertise



Dr Greg Pullen - Chief Operations Manager

- Over 20 years experience in the pharmaceutical and biotechnology industry
- Experience in business development, IP management and commercialisation



Ms Rolee Kumar - Director Business Development

- Over 8 years commercial biotechnology and molecular biology experience
- Complementary knowledge and expertise in business management and science

PHYLOGICA
BEYOND ANTIBODIES

Phylogica Value


discovering new drug candidates

- Phylogica is developing a pipeline of drug candidates in stroke, diabetes, asthma and rheumatoid arthritis
- Our lead drug candidates in the stroke area have successful preclinical trial results
- Phylogica has developed a unique and valuable drug discovery technology that is being applied to develop a range of new drug candidates

PHYLOGICA
BEYOND ANTIBODIES

Apoptotic brain damage in Stroke

- Long Term Apoptosis is Significant Cause of Long Term Damage




Phylomers inhibit $\text{TNF}\alpha$ induced apoptosis of PC12 cells


Exposure of PC12 cells to $\text{TNF}\alpha$ induces apoptosis

Addition of $4\mu\text{M}$ peptide reduces apoptotic cell death


$\text{TNF}\alpha$ only





+SP36



+SP71




+SP34



2) 32)




Peptides inhibit apoptosis: Primary neuronal ischemia model



CA1 neuronal protection following global cerebral ischaemia and treatment with c-Jun inhibitory Phylomers (*in vivo*)


Sham: no ischaemia




CA1
Neurons




Ischaemia: no treatment




Ischaemia: D35



Ischaemia: D36



Phylomer® Technology



Libraries contain millions of independent clones (Phylomer - parts of proteins)


Phylomer® libraries potentially cover every possible class of peptide shape

PHYLOGICA
BEYOND ANTIBODIES

Intellectual Property


integrated patent portfolio

- All intellectual property is wholly owned by Phylogica
- 8 patent families, 6 granted patents including key US, EU and Australian markets
- 8 patent applications undergoing national phase examination
- 3 International (PCT) and 2 provisional patent applications filed



PHYLOGICA
BEYOND ANTIBODIES

Internal Pipeline => Inflammation



Collaborators

NMRI

Uni of Melbourne

Garvin Institute

UWA

Blockers of these targets are suitable for treating multiple disease indications

PHYLOGICA
BEYOND ANTIBODIES

Business Model

realising value

- Phylogica has a unique peptide drug discovery technology (Phylomers)

- We will license our lead drug candidates with preclinical data packages (stroke, asthma, RA and diabetes)

- Phylomer technology is being partnered for target validation and co-development of new drug leads

- R&D collaborations and grants are important to leveraging the technology into new diseases



Global Biotech Comparators

realising value

There are several examples where biotechnology companies own similar drug discovery platforms

Cambridge Antibody Technologies owns a library for antibody development and is valued at around £360m

Medarex owns a platform for humanising antibodies and is currently valued at around US\$400m

Trimeris owns half of Fuzeon, an anti AIDS peptide in a co-development deal with Roche and is valued at around US\$280m

Phylogica Limited

Beyond Antibodies

www.phylogica.com

ASX Code PYC

Dr Stewart Washer

Chief Executive Officer

stewartw@phylogica.com

+61 418 288 212

Dr Greg Pullen

Chief Operating Officer

gregp@phylogica.com

+61 408 200 885

